Can Clinical Research Data Be Uploaded to an AI Tool?

Can Patient or Clinical Study Data Be Put Into an AI System?

AI can potentially help researchers summarize clinical notes, classify records, extract variables, analyze images, identify patterns, assist with coding, or work with large clinical research datasets. The attraction is obvious, especially when the alternative involves thousands of records and a research assistant developing a personal relationship with Excel.

Clinical research data, however, can carry unusually consequential privacy and governance obligations. A dataset may contain diagnoses, treatment histories, laboratory results, medication records, genomic information, dates, medical images, clinical narratives, patient identifiers, or combinations of information that reveal identity.

Whether such data can be uploaded to an AI tool cannot be answered by asking only whether the tool is secure. You need to determine what data you have, which legal and research rules govern them, whether the proposed AI provider is authorized to receive them, and whether the study's consent and ethics arrangements permit the processing.

Clinical Research Data Require a Higher Level of Verification

Clinical Data Bring Several Layers of Responsibility Together

“Clinical Research Data” Covers Very Different Information

The term can refer to data collected specifically for a clinical trial, information abstracted from medical records, laboratory measurements, adverse-event reports, patient-reported outcomes, imaging, genomic information, clinical notes, biospecimen-linked data, wearable-device measurements, or other health-related records.

Those materials do not necessarily fall under identical rules. Their legal status may depend on who collected them, why they were collected, whether they remain identifiable, which institution controls them, the jurisdiction, and whether another agreement governs their use.

Begin by classifying the data rather than beginning with the AI tool.

Health Information Can Be Both Sensitive and Highly Identifying

Clinical datasets often contain obvious identifiers such as names, medical record numbers, addresses, telephone numbers, email addresses, account information, photographs, or device identifiers. They may also contain dates, rare diagnoses, unusual treatment histories, small geographic areas, or combinations of characteristics capable of identifying a person.

The consequences of disclosure may also be substantial. Health records can reveal physical and mental health conditions, reproductive information, substance use, genetic characteristics, disability, treatment histories, and other information participants reasonably expect to be handled carefully.

This combination of identifiability and sensitivity is why clinical datasets generally deserve more scrutiny than an ordinary research spreadsheet.

HIPAA Is Important, but It Is Not a Universal Global Rule

Researchers frequently use “HIPAA” as shorthand for health-data privacy. That can create confusion outside the specific U.S. settings in which the law applies.

The HIPAA Privacy Rule protects most individually identifiable health information held or transmitted by covered entities and their business associates. HHS calls this protected health information, or PHI. The Privacy Rule regulates uses and disclosures of PHI and provides specific methods for de-identifying health information.

But HIPAA does not govern every researcher, every health dataset, or every country. Other U.S. federal and state rules may apply in particular settings, and researchers in other jurisdictions must follow their own privacy, health, research, professional, and institutional requirements.

Under HIPAA, Identifiable Health Information and De-Identified Information Are Treated Differently

In contexts where the HIPAA Privacy Rule applies, HHS states that protected health information includes individually identifiable health information held or transmitted by covered entities or business associates. Uses and disclosures of PHI are permitted only under conditions established by the Rule or an individual's valid authorization, subject to its detailed provisions and exceptions.

HIPAA also provides two methods for de-identifying PHI: Expert Determination and Safe Harbor. Under Expert Determination, a qualified person applies accepted statistical and scientific principles and determines that the risk is very small that the anticipated recipient could identify an individual using the information alone or in combination with other reasonably available information. Safe Harbor requires removal of specified identifiers and no actual knowledge that the remaining information could identify an individual.

HHS notes that properly de-identified information retains some identification risk, although that risk is expected to be very small under the HIPAA standard. Once information satisfies HIPAA's de-identification requirements, it is no longer PHI under the Privacy Rule.

These are specific U.S. HIPAA rules. They should not be copied into a study governed by another jurisdiction and assumed to constitute a universal anonymization standard.

Removing the Patient's Name Does Not De-Identify a Clinical Record

A clinical record can contain many identifiers beyond a name. Under HIPAA's Safe Harbor method, for example, the list of identifiers includes geographic information below specified levels, most date elements directly related to an individual, telephone and fax numbers, email addresses, Social Security numbers, medical record numbers, health-plan numbers, account numbers, certificate and license numbers, vehicle and device identifiers, URLs, IP addresses, biometric identifiers, full-face photographs, and other unique identifying characteristics or codes.

The list illustrates a broader research lesson even when HIPAA does not apply: health records are information-rich.

Clinical narratives deserve particular care. HHS explicitly states that HIPAA's de-identification requirements apply to identifiers wherever they appear, including free text, and observes that clinical narratives documenting patient history or lifestyle may contain context that readily allows identification.

Before using AI, researchers should therefore establish whether the clinical data have actually been de-identified to the required standard rather than equating de-identification with removal of the patient-name field.

Clinical Images Can Contain Identifiers Inside and Outside the Image

Medical images create their own challenges. Identifying information may appear in visible annotations, associated metadata, filenames, study identifiers, or other accompanying records. Some images may also contain inherently identifying features.

Under HIPAA's Safe Harbor framework, full-face photographs and comparable images are among the specified identifiers, while biometric identifiers such as fingerprints and voice prints are also listed.

Researchers working with photographs, scans, or other participant images should therefore separately assess whether participant-containing research images can be uploaded to AI rather than assuming that removal of a textual name solves the issue.

Genomic and Other High-Dimensional Data Complicate Anonymity

Some clinical research datasets are inherently information-rich. Genomic data are an obvious example, but longitudinal health records, detailed wearable data, rare-disease datasets, and other high-dimensional information can also create distinctive patterns.

SACHRP has emphasized that AI and large datasets challenge traditional concepts of identifiability because information can be combined across sources and used to generate or infer private information. The committee specifically notes that combinations of datasets may identify individuals even when no single dataset is independently identifying.

That makes the possibility that AI could contribute to re-identification particularly relevant for rich clinical datasets.

An AI Provider May Become Part of the Data-Handling Chain

Sending clinical information to an external AI service is not equivalent to running an analysis entirely inside an approved institutional environment. The external service may receive, process, retain, route, or otherwise handle information according to its technical architecture and contractual terms.

Where HIPAA applies, an outside organization performing certain functions involving PHI on behalf of a covered entity may be a business associate, with corresponding contractual and regulatory implications. A generic promise that a service is “HIPAA compliant” should not substitute for determining the parties' actual roles and required agreements.

In other jurisdictions, different controller, processor, outsourcing, or data-sharing concepts may apply. The broader question of whether AI processing constitutes sharing participant data with a third party therefore deserves explicit consideration.

Processing Location May Create Additional Requirements

Cloud AI systems may process information in infrastructure located outside the researcher's institution or country. International transfers of personal or health information may trigger additional legal, contractual, or institutional requirements.

Researchers should determine where the AI provider processes participant data and whether that location matters under the framework governing the study.

This is particularly important for multinational research, where a dataset may simultaneously be subject to sponsor requirements, local law, institutional agreements, ethics conditions, and cross-border transfer restrictions.

Consent and Ethics Approval Remain Separate From Technical Security

An AI environment can have excellent encryption and security controls while the proposed use remains outside what participants were told or what the ethics committee approved.

Clinical research protocols may describe data recipients, storage systems, confidentiality safeguards, secondary uses, and analytical procedures in considerable detail. Introducing an external AI system can potentially alter those arrangements.

If the AI processing was not anticipated when the study began, determine whether existing participant consent covers the new use and whether an ethics amendment or other institutional review is required.

De-Identification Does Not Automatically Resolve the Ethical Question

Successful de-identification may materially change the privacy-law analysis. Under HIPAA, for example, information properly de-identified according to the Rule is no longer PHI.

That does not establish that every subsequent AI use is automatically consistent with research ethics, institutional commitments, contractual restrictions, scientific validity, or participants' reasonable expectations.

The distinction matters because de-identification alone does not settle whether an AI use is ethically appropriate.

Clinical AI Outputs Require Validation, Not Just Privacy Protection

Even when data governance is fully resolved, AI output can create methodological risk. A generative model may omit clinically important information, incorrectly summarize a record, misclassify an event, fabricate a detail, or transform nuanced clinical language into a misleading simplification.

If AI-derived information becomes part of a research dataset, researchers need a validation procedure appropriate to the consequences of error. The more consequential the output, the less defensible it is to treat plausible-looking model output as ground truth.

Privacy approval answers whether the data may be processed. It does not answer whether the processing is scientifically valid.

Why a Clinical Dataset Needs More Than a Quick AI Upload

Common Mistakes With Clinical Research Data and AI

Use the Most Controlled Environment the Data Require

The starting question for clinical research should be, “What protections does this dataset require?” Only then should you ask which AI system, if any, can operate within those requirements.

A public consumer chatbot should not become the default simply because it is convenient. Depending on the study, the appropriate environment might instead be an institutionally contracted service, an approved cloud environment, an API operating under specific contractual conditions, a locally deployed model, or no external AI processing at all.

There are cases where the compliance and privacy burden will simply outweigh the value AI adds. That is not technological timidity. It is a legitimate research decision, particularly when a conventional analytical workflow can answer the question without introducing an additional external processor or disclosure pathway.

Before Uploading Clinical Research Data to AI

Questions About Clinical Research Data and AI

Clinical Data Should Enter AI Only Through an Authorized Research Environment

How to Cite This Guide

This guide is intended to be read, shared, and used in research, teaching, and academic work. If you draw on its ideas, explanations, or other content, please acknowledge the source by citing the guide. Doing so gives appropriate credit and helps your readers locate the original resource.